Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 November 2025 | Story Onthatile Tikoe | Photo Supplied
CartZA
The CartZA team (from the left): Richard Molefe (CEO), Kenny Netshitanzwani (COO), Tshepo Lencoe (CMO), and Lehlohonolo Molaba Duncan (CTO), UFS students driving innovation through technology.

In an inspiring display of innovation and collaboration, a group of University of the Free State (UFS) students have reimagined campus convenience through CartZA, a student-developed food delivery app that is transforming how students access meals and services. What began as a late-night idea during exam season has grown into one of the university’s proudest examples of student entrepreneurship.

 

From late-night hunger to a campus-wide solution

The idea for CartZA was born in November 2024, when Kenny Netshitanzwani, now Chief Operations Officer, and Tshepo Lencoe, now Chief Marketing Officer, found themselves waiting endlessly in queues at the Thakaneng Bridge during a late-night study session. “We waited nearly 40 minutes just to get food and thought, what if students could order in advance and collect without waiting?” recalls Netshitanzwani.

By December 2024, the two self-taught developers began building a website prototype from their homes. They tested the concept through an online poll that received an overwhelming 97% approval from 425 students. On 27 February 2025, they launched the website during Ms Winnie Sereeco’s entrepreneurship lecture, processing ten orders on the first day and more than a hundred by the end of the semester.

Their pitch attracted Lehlohonolo Molaba Duncan, now Chief Technology Officer – a BCom Finance student and systems architect who joined to develop the mobile app. Later, he introduced Richard Molefe, a BCom Honours in Finance student with strong corporate and leadership experience, who became Chief Executive Officer, completing the CartZA founding team.

 

Turning queues into clicks

By August 2025, the team had launched a fully functional app available on Google Play and the Apple App Store. Within weeks, it had surpassed 1 200 downloads, now exceeding 2 000. The app allows users to order ahead for collection or opt for delivery, with CartZA’s slogan, ‘Add to Cart and Cut the Queue,’ capturing its mission to simplify student life through technology and convenience.

 

Overcoming challenges and gaining recognition

The journey was not without challenges. The team self-funded the project through allowances and side hustles, even borrowing a fellow student’s MacBook, affectionately known as Comfort the Barber, to publish on Apple’s platform. Their breakthrough came when The Deli restaurant joined the platform, expanding access to more outlets.

Their innovation has since gained recognition across the province. CartZA was named among the Free State Top 10 in the Youth Innovation Challenge, hosted by the Young African Entrepreneurs Institute and Absa Bank, and will represent the province at the national finals in November. The team also received the Student Entrepreneurial Excellence Award at the 2025 Executive Director of Student Affairs (EDSA) Prestige Awards.

Beyond convenience, CartZA now employs 15 active student delivery partners and has 30 more registered on standby across Bloemfontein, empowering peers while reshaping campus life.

 

Looking ahead

With plans to expand to other universities, CartZA aims to become a nationwide lifestyle platform connecting students, service providers, and opportunities. “Our journey shows that innovation starts with identifying the needs around you,” says Molefe. “CartZA is proof that when students collaborate and persist, they can create meaningful change.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept